Treflucan 150 mg 1 capsule

Tradename

Treflucan

Treflucan

Composition

Each capsule contains:

Fluconazole 150mg

Auxiliary components:

lactose, microcrystalline cellulose, magnesium stearate, sodium lauryl sulfate.

Properties

Fluconazole is a triazole antifungal agent. Its main mode of action is to inhibit the synthesis of sterols in the fungal cell. Fluconazole has a high specificity in relation to fungal enzymes dependent on cytochrome P-450. Blocks the conversion of lanosterol of fungal cells into a membrane lipid — ergosterol; increases the permeability of the cell membrane, disrupts growth and replication. Fluconazole, being highly selective for cytochrome P450 of fungi, practically does not inhibit these enzymes in

the human body (in comparison with itraconazole, clotrimazole, econazole and ketoconazole, it suppresses oxidative processes in human liver microsomes to a lesser extent, dependent on cytochrome p450).

Indications

For adults for treatment — vaginal candidiasis, acute or recurrent; candidal balanitis when local therapy is not appropriate.

Dermatomycosis, including foot fungus, ringworm, inguinal fungus, pityriasis versicolor, and candidal skin infections when systemic therapy is indicated. Onychomycosis when other agents are not considered suitable. To prevent a decrease in the frequency of relapses of vaginal candidiasis (4 or more episodes per year). Prevention of candidal infections in patients with long-term neutropenia (for example, in patients with hematologic malignancies receiving chemotherapy or in patients receiving hematopoietic stem cell transplantation).

Mode of application:

Contraindications

Hypersensitivity to fluconazole or related azole compounds or any of the other ingredients in the formulation.

Precautions:

Use caution in patients with renal and hepatic dysfunction. Treflucan has been associated with rare cases of severe liver toxicity. In cases of hepatotoxicity associated with fluconazole, there was no clear relationship with the total daily dose, duration of therapy, gender or age of the patient. It is reversible when the therapy is stopped. The patient should be informed of the symptoms of a serious hepatic effect (asthenia, anorexia, persistent nausea, vomiting and jaundice are important).

Side effects

Most common: headache, abdominal pain, diarrhea, nausea, vomiting, elevated alkaline phosphatase levels, and rash. Diseases of the blood and lymphatic system: anemia. Rarely: agranulocytosis, leukopenia, thrombocytopenia, neutropenia. Immune system disorders: rare anaphylaxis. Metabolism and nutritional disorders: infrequently: decreased appetite. Rarely:

hypercholesterolemia, hypertriglyceridemia, hypokalemia. Mental disorders: drowsiness, insomnia. Nervous system disorders: infrequently: convulsions, paresthesia, dizziness, taste perversion. Rare: tremor. Gastrointestinal disorders: infrequently:

constipation, dyspepsia, flatulence, dry mouth. Rare: liver failure, hepatocellular necrosis, hepatitis, hepatocellular damage. Diseases the skin and subcutaneous tissue: general: rash. Uncommon: drug rash, urticaria, itching, increased sweating. Rare: anqioedema, facial

Storage

Store at 25C in a dry place out of reach of children.

Packaging:

The cardboard box contains a blister with 1 capsule and paper instructions.